Category Archives: crizotinib – Xalkori from Pfizer

Article by Dr. Shaw

Dr. Shaw discusses the recent approval of Alectinib and the treatment implications now that there are 3 ALK inhibitors approved by the FDA. http://www.ascopost.com/issues/january-25-2016/the-evolving-treatment-landscape-of-alk-positive-nsclc/

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Imunotherapies, Lung cancer, Potential Treatments, Research | Leave a comment

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

Patients taking Pfizer’s Lorlatinib (after developing resistance to Crizotinib) can develop the L1198F mutation. The L1198F mutation causes the cancer cells that were previously resistant to Crizotinib to become sensitive to Crizotinib again. Essentially the two drugs can require mutually … Continue reading

Posted in 3922 - lorlatinib by Pfizer, Brain metastases, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research, Resistance to treatment | Leave a comment

Alectinib approved by FDA

The FDA conditionally approved alectinib (brand name Alecensa) on December 11, 2015 as a second line treatment. This approval came less than 3 months after the FDA application was filed. The approval was based on results from two single-arm clinical trials. … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Regulatory applications & approvals, Research, Side Effects | Leave a comment

Editorial on Brain mets and ALK lung cancer

The Journal of Clinical Oncology has an editorial about the current research on treating brain mets for ALK+ patients that discusses ALK inhibitors and different kinds of radiation treatments. Treatments discussed include: 1) Crizotinib, 2) Ceritinib 3) Alectinib 4) brigatinib, … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research, Resistance to treatment, Side Effects | Leave a comment

European Commission expands use of Crizotinib

Around 12-2-2015 the Europe Commission approved Xalkori (Crizotinib) as a first line treatment so it can be given before chemotherapy.

Posted in crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Regulatory applications & approvals | Leave a comment

Survey of ALK inhibitors effects on brain mets

This survey summarizes the results of other research to describe the current level of knowledge about how effective different ALK inhibitors are at treating brain mets. Inhibitors that are discussed include crizotinib, ceritinib, alectinib, AP26113 (brigatinib) and PF-06463922 (lorlatinib). http://www.thecco.net/article/view/6520/7543

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research | Leave a comment

Comparison of different diagnostic tests

A comparison of the Fluorescence in-situ hybridization (FISH) test and ALK immunohistochemistry (IHC) for determining ALK + status. Basically the tests have results that are 99% consistent. The authors argue that either test should be sufficient on its own to determine … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research | Leave a comment

2 abstracts on Crizotinib

Please see glossary for definitions of acronyms. Abstract 19135 is a survival comparison study of 3 ways of detecting the ALK fusion gene. This study was done in China and involved 75 (and possibly 98 patients). The abstract refers to … Continue reading

Posted in crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research, Resistance to treatment | Leave a comment

Novartis update

On May 8, 2015 Novartis announced that Zykadia (ceritinib) was approved by the European Commission to treat ALK+ lung cancer patients previously treated with Crizotinib.

Posted in ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer | Leave a comment

Crizotinib followed by Ceritinib

A retrospective study of 73 patients who took Crizotinib followed by Ceritib  from 4 hospitals found positive results. The median progression free survival (PFS) on Crizotinib was 8.2 months. The median interval before starting Ceritinib was 25 days. The median … Continue reading

Posted in ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Research | Leave a comment